TY - JOUR
T1 - Targeting CD73 to augment cancer immunotherapy
AU - Roh, Meejeon
AU - Wainwright, Derek A.
AU - Wu, Jennifer D.
AU - Wan, Yong
AU - Zhang, Bin
N1 - Funding Information:
This research was in part supported by National Institutes of Health grant CA149669 , CA208354 and CA222963 , and Northwestern University RHLCCC NCI CCSG P30 CA060553 .
Publisher Copyright:
© 2020 The Authors
PY - 2020/8
Y1 - 2020/8
N2 - CD73 (ecto-5′-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism to protect them from immune attack. In particular, inducible expression of CD73 along with other adenosinergic molecules on both cancer cells and host cells sustains immunosuppressive tumor microenvironment by affecting multiple aspects of the immune response. Owing to its multifaceted capacity to tumor promotion as an emerging immune checkpoint, CD73 is an ideal therapeutic target for cancer treatment especially in combination with conventional therapy and/or other immune checkpoint inhibitors. In this review, we will discuss the roles of CD73 on tumor and immune cells and will highlight the therapeutic value of CD73 for combination therapy.
AB - CD73 (ecto-5′-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism to protect them from immune attack. In particular, inducible expression of CD73 along with other adenosinergic molecules on both cancer cells and host cells sustains immunosuppressive tumor microenvironment by affecting multiple aspects of the immune response. Owing to its multifaceted capacity to tumor promotion as an emerging immune checkpoint, CD73 is an ideal therapeutic target for cancer treatment especially in combination with conventional therapy and/or other immune checkpoint inhibitors. In this review, we will discuss the roles of CD73 on tumor and immune cells and will highlight the therapeutic value of CD73 for combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=85089136056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089136056&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2020.07.001
DO - 10.1016/j.coph.2020.07.001
M3 - Review article
C2 - 32777746
AN - SCOPUS:85089136056
VL - 53
SP - 66
EP - 76
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
ER -